About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study

ASCO Annual MeetingThe Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio's existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform. The consortium includes top pharmaceutical giants such as AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson, Novartis, and Roche.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528545627/en/

PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study (Graphic: Business Wire)

PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study (Graphic: Business Wire)

Background

Manual screening of patients for cancer trials is traditionally a resource-intensive process, taking about 25 minutes per trial and limiting patient access to suitable trials. This not only restricts available trial options but also adversely impacts enrollment rates. In response, Massive Bio and the PCC implemented an advanced multi-trial matching method that integrates Next-Generation Sequencing (NGS) results and utilizes AI to enhance both the accuracy and efficiency of trial matching, particularly for targeted therapies.

Methods

Massive Bio’s established AI system uses computer vision and natural language processing to extract 180 structured clinical parameters from medical records, and has been optimized using GPT-4 Large Language Model (LLM) and fine-tuned for the oncology and biomarker-specific use case. This system matches patients to digitized inclusion/exclusion criteria of more than 14,000 actively recruiting interventional cancer trials, using an AI-driven recommendation algorithm.

Key Findings

  • Patient Data Analysis: From a dataset of 5,707 cancer patients, only 1,557 (27%) had accessible NGS testing results.
  • Trial Matching Improvements: The study matched 690 unique patients to at least one trial, creating 1,254 patient-trial pairs—a 1.82-fold increase due to the multi-trial matching approach.
  • Potential Increase with Full NGS: Assuming full NGS testing availability, the study projected 2,635 matching pairs, indicating a potential 2.1-fold increase.
  • Targeted Therapy Case Study: In lung cancer trials focusing on the EGFR gene, matching surged to a 12.4-fold increase for unique patients.
  • Matching Efficiency: The system matched or exceeded theoretical rates in 80% of trials, significantly reducing manual effort with an estimated savings of 19,500 hours (nearly 100% efficiency).

Conclusion

The fusion of NGS and AI in a multi-trial matching framework has not only nearly doubled the potential eligibility for patients across various tumor types but also achieved a twelve-fold increase in matching efficiency for specific tumor profiles, significantly curtailing manual labor.

Future Directions

Further nationwide analysis is under consideration to expand upon these promising results.

Reference:

Kurnaz S, Loaiza-Bonilla A, Carvallo Castaneda D, Huner O. Effect of a novel artificial intelligence (AI) –enabled multi-trial matching system on patient matching using real-world data. J Clin Oncol 42, 2024 (suppl 16; abstr e13501). 2024 ASCO Annual Meeting.

About the Precision Cancer Consortium (PCC)

The Precision Cancer Consortium comprises pharmaceutical and biotechnology companies dedicated to advancing precision oncology to improve patient outcomes by increasing access to comprehensive genomic testing and addressing precision diagnostics gaps. For more information, visit Precision Cancer Consortium.

About Massive Bio

Massive Bio empowers cancer patients to find optimal treatment options, utilizing AI to improve equitable access and precision in clinical trial matching, drug matching, and drug development. The company collaborates with numerous pharmaceutical companies, CROs, and hospital networks and has a global presence with nearly 100 personnel across 12 countries. Follow @MassiveBio on social media.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.